Epizyme planning $140 million follow-on

Cancer company Epizyme Inc. (NASDAQ:EPZM) proposed to raise $140 million in a follow-on underwritten by Citigroup; Cowen; Leerink; JMP Securities; Wedbush PacGrow; and BTIG. Earlier this month, Epizyme jumped $15.49 (76%) to $35.99 after receiving milestone payments from partners Celgene Corp. (NASDAQ:CELG) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) (see BioCentury, Jan. 13). ...